6 Heddon Street
London W1B 4BT
United Kingdom
https://genflowbio.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 5
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Eric Jean Leire M.D., MBA | Founder, CEO & Executive Director | 232,01k | N/D | 1958 |
Dr. Cedric Szpirer | Head of CMC | N/D | N/D | N/D |
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
L'ISS Governance QualityScore di Genflow Biosciences plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.